Show simple item record

dc.contributor.authorEmilsson, Brynjar
dc.contributor.authorGudjonsson, Gisli
dc.contributor.authorSigurdsson, Jon F
dc.contributor.authorBaldursson, Gisli
dc.contributor.authorEinarsson, Emil
dc.contributor.authorOlafsdottir, Halldora
dc.contributor.authorYoung, Susan
dc.date.accessioned2012-05-14T13:57:10Z
dc.date.available2012-05-14T13:57:10Z
dc.date.issued2011-07-25
dc.date.submitted2012-05-14
dc.identifier.citationBMC Psychiatry 2011,11:116en_GB
dc.identifier.issn1471-244X
dc.identifier.pmid21787431
dc.identifier.doi10.1186/1471-244X-11-116
dc.identifier.urihttp://hdl.handle.net/2336/223573
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractBACKGROUND: Attention deficit hyperactivity disorder (ADHD) in adulthood is not fully treated by psychopharmacological treatment alone. The main aim of the current study was to evaluate a newly developed cognitive behaviour therapy (CBT) based group programme, the Reasoning and Rehabilitation for ADHD Youths and Adults (R&R2ADHD), using a randomized controlled trial. METHODS: 54 adults with ADHD already receiving psychopharmacological treatment were randomly allocated to an experimental (CBT/MED) treatment condition (n = 27) and a 'treatment as usual' (TAU/MED) control condition (n = 27) that did not receive the CBT intervention. The outcome measures were obtained before treatment (baseline), after treatment and at three month follow-up and included ADHD symptoms and impairments rated by independent assessors, self-reported current ADHD symptoms, and comorbid problems. RESULTS: The findings suggested medium to large treatment effects for ADHD symptoms, which increased further at three month follow-up. Additionally, comorbid problems also improved at follow-up with large effect sizes. CONCLUSIONS: The findings give support for the effectiveness of R&R2ADHD in reducing ADHD symptoms and comorbid problems, an improving functions associated with impairment. The implications are that the benefits of R&R2ADHD are multifaceted and that combined psychopharmacological and CBT based treatments may add to and improve pharmacological interventions.
dc.description.sponsorshipRANNIS the Icelandic Centre for Research 080443022 Landspitali Science Fund Janssen-Cilag, Iceland Janssen-Cilag Shire Novatis Eli-Lilly Flynn-Pharmaen_GB
dc.language.isoenen
dc.publisherBioMed Centralen_GB
dc.relation.urlhttp://dx.doi.org/10.1186/1471-244X-11-116en_GB
dc.rightsArchived with thanks to BMC psychiatryen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAttention Deficit Disorder with Hyperactivityen_GB
dc.subject.meshCentral Nervous System Stimulantsen_GB
dc.subject.meshCognitive Therapyen_GB
dc.subject.meshCombined Modality Therapyen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshPsychiatric Status Rating Scalesen_GB
dc.subject.meshPsychotherapy, Groupen_GB
dc.subject.meshSelf Reporten_GB
dc.titleCognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial.en
dc.typeArticleen
dc.contributor.departmentKing's College London, Institute of Psychiatry, De Crespigny Park, London, UK.en_GB
dc.identifier.journalBMC psychiatryen_GB
html.description.abstractBACKGROUND: Attention deficit hyperactivity disorder (ADHD) in adulthood is not fully treated by psychopharmacological treatment alone. The main aim of the current study was to evaluate a newly developed cognitive behaviour therapy (CBT) based group programme, the Reasoning and Rehabilitation for ADHD Youths and Adults (R&R2ADHD), using a randomized controlled trial. METHODS: 54 adults with ADHD already receiving psychopharmacological treatment were randomly allocated to an experimental (CBT/MED) treatment condition (n = 27) and a 'treatment as usual' (TAU/MED) control condition (n = 27) that did not receive the CBT intervention. The outcome measures were obtained before treatment (baseline), after treatment and at three month follow-up and included ADHD symptoms and impairments rated by independent assessors, self-reported current ADHD symptoms, and comorbid problems. RESULTS: The findings suggested medium to large treatment effects for ADHD symptoms, which increased further at three month follow-up. Additionally, comorbid problems also improved at follow-up with large effect sizes. CONCLUSIONS: The findings give support for the effectiveness of R&R2ADHD in reducing ADHD symptoms and comorbid problems, an improving functions associated with impairment. The implications are that the benefits of R&R2ADHD are multifaceted and that combined psychopharmacological and CBT based treatments may add to and improve pharmacological interventions.


This item appears in the following Collection(s)

Show simple item record